HUTCHMED (China) Limited
HCM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.03 | -0.24 | -0.10 | -0.73 |
| FCF Yield | -0.71% | 6.06% | -12.19% | -3.97% |
| EV / EBITDA | 170.21 | 42.81 | -5.53 | -25.12 |
| Quality | ||||
| ROIC | -3.98% | 1.93% | -60.28% | -33.92% |
| Gross Margin | 44.64% | 54.12% | 27.04% | 27.49% |
| Cash Conversion Ratio | 0.01 | 2.18 | 0.75 | 1.22 |
| Growth | ||||
| Revenue 3-Year CAGR | 13.91% | 33.01% | 23.21% | 20.23% |
| Free Cash Flow Growth | -109.34% | 161.14% | -38.14% | -170.66% |
| Safety | ||||
| Net Debt / EBITDA | -4.55 | -2.94 | 0.71 | 1.63 |
| Interest Coverage | -15.22 | 24.21 | -628.48 | -581.57 |
| Efficiency | ||||
| Inventory Turnover | 6.92 | 7.65 | 5.49 | 7.22 |
| Cash Conversion Cycle | 105.40 | 78.76 | 91.55 | 143.75 |